Ginkgo Bioworks Q2 FY26 GAAP net loss widens to $57 million; revenue drops 48% to $20 million

• Ginkgo Bioworks posted Q2 2026 revenue of USD 20 million, down 48% on ongoing program rationalization tied to restructuring.
• GAAP net loss from continuing operations widened to USD 57 million.
• Adjusted EBITDA loss widened to USD 36 million.
• Cash, cash equivalents and marketable securities totaled USD 302 million at June 30, 2026; full-year cash burn outlook reaffirmed at USD 150-125 million.
• Won government-backed autonomous lab work at MIT, Caltech, Northwestern and the University of Maryland; began a USD 47 million build at PNNL’s EMSL.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ginkgo Bioworks Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-053319), on August 05, 2026, and is solely responsible for the information contained therein.